GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (FRA:45O) » Definitions » Debt-to-Revenue

Orgenesis (FRA:45O) Debt-to-Revenue : 49.24 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Orgenesis Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Orgenesis's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €3.23 Mil. Orgenesis's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €22.37 Mil. Orgenesis's annualized Revenue for the quarter that ended in Mar. 2024 was €0.52 Mil. Orgenesis's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 49.24.


Orgenesis Debt-to-Revenue Historical Data

The historical data trend for Orgenesis's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Debt-to-Revenue Chart

Orgenesis Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.53 1.69 0.33 0.56 42.68

Orgenesis Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.62 45.81 49.46 34.34 49.24

Competitive Comparison of Orgenesis's Debt-to-Revenue

For the Biotechnology subindustry, Orgenesis's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orgenesis's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Orgenesis's Debt-to-Revenue falls into.



Orgenesis Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Orgenesis's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.259 + 17.484) / 0.486
=42.68

Orgenesis's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.23 + 22.374) / 0.52
=49.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Orgenesis Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Orgenesis's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis (FRA:45O) Business Description

Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.

Orgenesis (FRA:45O) Headlines

No Headlines